Pradaxa Heart Attack Side Effects:
New Study Highlights Potential Risk

A new study suggests that the blood thinner Pradaxa may be linked to an increased risk of heart attacks. While the lawyers at Saiontz & Kirk, P.A. are actively investigating potential Pradaxa lawsuits for individuals who have experienced severe bleeding, potential Pradaxa heart attack lawsuits are also being considered.

Pradaxa (dabigatran) is a new drug that was just approved in October 2010, yet has already been linked to a number of serious and potentially life-threatening side effects. Pradaxa was introduced by Boehringer Ingelheim as an alternative to Coumadin/warfarin, and is supposed to be easier to use and require less monitoring. However, Pradaxa side effects may actually pose a greater risk to consumers than the drug maker originally disclosed.

A study published this week by the Archives of Internal Medicine looked at seven different clinical trials involving Pradaxa and found that out of 20,000 patients who took the newer blood thinner, 237 suffered heart attacks or chest pain, compared with only 83 patients out of 10,514 who took warfarin or a pacebo.

Although Pradaxa has only been on the market for a little more than one year, the FDA is already investigating the potential risk of Pradaxa bleeding problems, after an alarming number of post-marketing reports surfaced involving hemorrhages and other internal bleeding. According to a report by the Wall Street Journal, the FDA indicated this week that it is also looking the potential Pradaxa heart attack side effects.

PRADAXA HEART ATTACK LAWSUIT EVALUATION

The Pradaxa lawyers at Saiontz & Kirk, P.A. are closely monitoring the data surrounding this new drug. Individuals throughout the United States may be entitled to financial compensation through a Pradaxa lawsuit if they have experienced severe or fatal bleeding problems after using the drug, or if they have suffered a heart attack from Pradaxa.

To review a potential claim for yourself, a friend or family member, request a free consultation and Pradaxa case evaluation.